Recent successes in AAV-mediated longevity gene therapies highlight both immense promise and critical delivery bottlenecks. While AAV-delivered Klotho extended male mouse lifespan by 19.7% and AAV-CMV-OSK increased remaining lifespan by 109% in aged males, a puzzling limitation remains: Klotho delivery mysteriously fails in younger (6-month-old) males. The current literature attributes this to low protein expression caused by hepatocyte regeneration, which actively dilutes the transduced cell burden.

I propose a distinct mechanistic explanation for this age/sex disparity and a targeted capsid-engineering solution to overcome it.

The Hypothesis

The failure of AAV-Klotho in young males is a pharmacokinetic artifact of sexually dimorphic, androgen-driven hepatic turnover that rapidly depletes episomal vector genomes. I hypothesize that utilizing next-generation, liver-detargeted myotropic AAV capsids to establish post-mitotic skeletal muscle as the primary secretory depot will completely rescue Klotho efficacy in young males and provide superior, life-long transgene expression across all demographics.

Mechanistic Rationale

1. The Episomal Dilution Problem: Standard AAV vectors (like natural AAV8 or AAV9) default to strong hepatic tropism. Because AAV genomes persist primarily as non-integrating episomes, cellular division results in rapid transgene dilution. Young male mice exhibit distinct growth hormone and androgen secretory profiles that drive higher baseline hepatocyte turnover compared to females or aged (12-month) males. Thus, the observed "failure" of Klotho in young males is fundamentally an issue of vector genome stability, not biological resistance to the Klotho protein itself.
2. Skeletal Muscle as a Durable Bio-Reactor: Skeletal myofibers are massive, highly vascularized, and definitively post-mitotic. Recent advances show that next-generation myotropic capsids with liver-detargeting mutations achieve uniform skeletal and cardiac muscle transduction at substantially lower doses. By shifting the transduction burden from a regenerative tissue (liver) to a stable tissue (muscle), episomal AAV-Klotho genomes will be indefinitely preserved without the need for genomic integration.

Proposed Experimental Design

To explicitly test and falsify this hypothesis, we must decouple the tissue depot from the payload efficacy:

• Cohorts: 6-month-old and 12-month-old wild-type mice (stratified by male/female).
• Vector Arms:
  1. Control (Vehicle)
  2. Standard AAV9-Klotho (Hepatic depot)
  3. Engineered MyoAAV-Klotho (Liver-detargeted, highly myotropic). We can leverage variants generated by ML frameworks that optimize multi-trait capsids for potency and biodistribution.
• Longitudinal Readouts:
  • Quantify circulating serum Klotho levels at 1, 3, 6, and 12 months post-injection.
  • Perform serial biopsies to assess vector genome copies per diploid cell (vg/cell) in both liver and quadriceps tissues over time, tracking exact episomal dilution rates.
  • Quality Control: Ensure orthogonal analytical validation (e.g., SEC-MALS, DLS, and mass spectrometry) during the production of these novel myotropic capsids, as engineered variants can display temperature-dependent aggregation mimicking degradation on standard capillary electrophoresis platforms.

Expected Outcomes & Implications

If my hypothesis holds, AAV9-Klotho will show a rapid decline in circulating Klotho and hepatic vg/cell specifically in 6-month-old males. Conversely, the MyoAAV-Klotho group will maintain stable, high-level circulating Klotho and high muscle vg/cell across all age and sex groups.

By establishing skeletal muscle as the optimal depot for secreted longevity factors, we can elegantly bypass the liver turnover barrier. This shifts systemic longevity gene therapy from a race against hepatic episomal dilution to a durable, single-dose intervention.